Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : Neuroscience -- Ignore unavailable to you. Want to Upgrade?

To: tommysdad who wrote (72)	9/27/2000 11:45:13 PM
From: scott_jiminez	Respond to of 278

tommysdad - there's quite a bit of evidence that estrogen has highly localized site(s) of activity (i.e. ER) and broader influences on multiple systems in the CNS. An example of a potential role for estrogen in Parkinson's disease ncbi.nlm.nih.gov:80/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_uids=10924688&dopt=Abstract I'd be curious to know if you're familiar with any citations showing specific orphan-ER-like localization in brain. Also - since I've not studied this much either - how does one take advantage of knowledge of an orphan GPCR (say orphan to a 'normal' cell surface receptor such as 5-HT1B or m1 muscarinic) in approaching a CNS pathology putatively involving that receptor?

To: tommysdad who wrote (72)	9/28/2000 1:23:52 AM
From: tuck	Read Replies (1) \| Respond to of 278

tommysdad, >> TLRK has NO GPCR program of which I am aware.<< Me, neither. Sloppy sentence construction on my part. Let's try "my guess is TLRK has a major lead in the latter." Meaning orphan receptors, not GPCRs. I certainly appreciate your distinctions among orphan receptors, thanks. >>the bullets seem to be flying hot and heavy here.<< I try to stay neutral on these things. I don't know much about the history amongst the antagonists and don't much care. If I like what they say on a certain topic, I'll talk to 'em. Thanks as always for your input. Cheers, Tuck